Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
Moderate - Severe Th2 (Type 2) High asthma, as defined by Forced Expiratory Volume in one second (FEV1) <90% predicted, on medium to high dose inhaled corticosteroids (ICS) with or without a second controller
Age > 18
Inhaled steroid doses of 500micrograms (mcg) per day or more (Fluticasone equivalent)
Reversibility >/= 12% at screening or within the past 2 years, or a positive methacholine challenge test within the past 2 years, or a positive methacholine challenge during screening
Pregnant, nursing, or unwilling to test for pregnancy
Current smoker or >10 pack year smoking history
Body Mass Index (BMI)>37
Respiratory infection in the last 30 days
Sally E. Wenzel MD
Lead sponsor
University of Pittsburgh
Sponsor institution